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Abstract
In many clinical trials studying neurodegenerative diseases such as Parkinson’s disease (PD),
multiple longitudinal outcomes are collected to fully explore the multidimensional impairment
caused by this disease. If the outcomes deteriorate rapidly, patients may reach a level of func-
tional disability sufficient to initiate levodopa therapy for ameliorating disease symptoms. An
accurate prediction of the time to functional disability is helpful for clinicians to monitor pa-
tients’ disease progression and make informative medical decisions. In this article, we first
propose a joint model that consists of a semiparametric multilevel latent trait model (MLLTM)
for the multiple longitudinal outcomes, and a survival model for event time. The two submod-
els are linked together by an underlying latent variable. We develop a Bayesian approach for
parameter estimation and a dynamic prediction framework for predicting target patients’ fu-
ture outcome trajectories and risk of a survival event, based on their multivariate longitudinal
measurements. Our proposed model is evaluated by simulation studies and is applied to the
DATATOP study, a motivating clinical trial assessing the effect of deprenyl among patients with
early PD.
Key Words: Area under the ROC curve, clinical trial, failure time, latent trait model.
∗Corresponding author: Sheng Luo is Associate Professor, Department of Biostatistics, The University of Texas
Health Science Center at Houston, 1200 Pressler St, Houston, TX 77030, USA (E-mail: sheng.t.luo@uth.tmc.edu;
Phone: 713-500-9554).
1
1 Introduction
Joint models of longitudinal outcomes and survival data have been an increasingly productive re-
search area in the last two decades (e.g., Tsiatis & Davidian, 2004). The common formulation of joint
models consists of a mixed effects submodel for the longitudinal outcomes and a semiparametric Cox
submodel (Wulfsohn & Tsiatis, 1997) or accelerated failure time (AFT) submodel for the event time
(Tseng et al., 2005). Subject-specific shared random effects (Vonesh et al., 2006) or latent classes
(Proust-Lima et al., 2014) are adopted to link these two submodels. Many extensions have been pro-
posed, e.g., relaxing the normality assumption of random effects (Brown & Ibrahim, 2003), replacing
random effects by a general latent stochastic Gaussian process (Xu & Zeger, 2001), incorporating
multivariate longitudinal variables (Chi & Ibrahim, 2006), and extending single survival event to
competing risks (Elashoff et al., 2007) or recurrent events (Sun et al., 2005; Liu & Huang, 2009).
Joint models are commonly used to provide an efficient framework to model correlated longitudi-
nal and survival data and to understand their correlation. A novel use of joint models, which gains
increasing interest in recent years, is to obtain dynamic personalized prediction of future longitudinal
outcome trajectories and risks of survival events at any time, given the subject-specific outcome pro-
files up to the time of prediction. For example, Rizopoulos (2011) proposed a Monte Carlo approach to
estimate risk of a target event and illustrated how it can be dynamically updated. Taylor et al. (2013)
developed a Bayesian approach using a Markov chain Monte Carlo (MCMC) algorithm to dynami-
cally predict both the continuous longitudinal outcome and survival event probability. Blanche et al.
(2015) extended the survival submodel to account for competing events. Rizopoulos et al. (2013)
compared dynamic prediction using joint models v.s. landmark analysis (van Houwelingen, 2007), an
alternative approach for dynamically updating survival probabilities. A key feature of these dynamic
prediction frameworks is that the predictive measures can be dynamically updated as additional
longitudinal measurements become available for the target subjects, providing instantaneous risk
assessment.
Most dynamic predictions via joint models developed in the literature have been restricted to
one or two longitudinal outcomes. However, impairment caused by the neurodegenerative diseases
such as Parkinson’s disease (PD) affects multiple domains (e.g., motor, cognitive, and behavioral).
The heterogeneous nature of the disease makes it impossible to use a single outcome to reliably
reflect disease severity and progression. Consequently, many clinical trials of PD collect multiple
longitudinal outcomes of mixed types (categorical and continuous). To properly analyze these longi-
tudinal data, one has to account for three sources of correlation, i.e., inter-source (different measures
at the same visit), longitudinal (same measure at different visits), and cross correlation (different
measures at different visits) (O’Brien & Fitzmaurice, 2004). Hence, a joint modeling framework for
analyzing all longitudinal outcomes simultaneously is essential. There is a large number of joint
modeling approaches for mixed type outcomes. Multivariate marginal models (e.g., likelihood-based
(Molenberghs & Verbeke, 2005), copula-based (Lambert & Vandenhende, 2002), and GEE-based
(O’Brien & Fitzmaurice, 2004)), provide direct inference for marginal treatment effects, but handling
unbalanced data and more than two response variables remain open problems. Multivariate random
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effects models (Verbeke et al., 2014) have severe computational difficulties when the number of ran-
dom effects is large. In comparison, mixed effects models focused on dimensionality reduction (using
latent variables) provide an excellent and balanced approach to modeling multivariate longitudinal
data. To this end, He & Luo (2016) developed a joint model for multiple longitudinal outcomes
of mixed types, subject to an outcome-dependent terminal event. Luo & Wang (2014) proposed
a hierarchical joint model accounting for multiple levels of correlation among multivariate longitu-
dinal outcomes and survival data. Proust-Lima et al. (2016) developed a joint model for multiple
longitudinal outcomes and multiple time-to-events using shared latent classes.
In this article, we propose a novel joint model that consists of: (1) a semiparametric multilevel
latent trait model (MLLTM) for the multiple longitudinal outcomes with a univariate latent variable
representing the underlying disease severity, and (2) a survival submodel for the event time data.
We adopt penalized splines using the truncated power series spline basis expansion in modeling the
effects of some covariates and the baseline hazard function. This spline basis expansion results in
tractable integration in the survival function, which significantly improves computational efficiency.
We develop a Bayesian approach via Markov chain Monte Carlo (MCMC) algorithm for statistical
inference and a dynamic prediction framework for the predictions of target patients’ future outcome
trajectories and risks of survival event. These important predictive measures offer unique insight into
the dynamic nature of each patient’s disease progression and they are highly relevant for patient tar-
geting, management, prognosis, and treatment selection. Moreover, accurate prediction can advance
design of future studies, experimental trials, and clinical care through improved prognosis and earlier
intervention.
The rest of the article is organized as follows. In Section 2, we describe a motivating clinical trial
and the data structure. In Section 3, we discuss the joint model, Bayesian inference, and subject-
specific prediction. In Section 4, we apply the proposed method to the motivating clinical trial
dataset. In Section 5, we conduct simulation studies to assess the prediction accuracy. Concluding
remarks and discussions are given in Section 6.
2 A motivating clinical trial
The methodological development is motivated by the DATATOP study, a double-blind, placebo-
controlled multicenter randomized clinical trial with 800 patients to determine if deprenyl and/or
tocopherol administered to patients with early Parkinson’s disease (PD) will slow the progression of
PD. We refer to as placebo group the patients who did not receive deprenyl and refer to as treatment
group the patients who received deprenyl. The detailed description of the design of the DATATOP
study can be found in Shoulson (1998).
In the DATATOP study, the multiple outcomes collected include Unified PD Rating Scale (UP-
DRS) total score, modified Hoehn and Yahr (HY) scale, Schwab and England activities of daily living
(SEADL), measured at 10 visits (baseline, month 1, and every 3 months starting from month 3 to
month 24). UPDRS is the sum of 44 questions each measured on a 5-point scale (0-4), and it is
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approximated by a continuous variable with integer value from 0 (not affected) to 176 (most severely
affected). HY is a scale describing how the symptoms of PD progresses. It is an ordinal variable
with possible values at 1, 1.5, 2, 2.5, 3, 4, and 5, with higher values being clinically worse outcome.
However, the DATATOP study consists of only patients with early mild PD and the worst observed
HY is 3. SEADL is a measurement of activities of daily living, and it is an ordinal variable with
integer values from 0 to 100 incrementing by 5, with larger values reflecting better clinical outcomes.
We have recoded SEADL variable so that higher values in all outcomes correspond to worse clinical
conditions and we have combined some categories with zero or small counts so that SEADL has eight
categories.
Among the 800 patients in the DATATOP study, 44 did not have disease duration recorded and
one had no UPDRS measurements. We exclude them (5.6%) from our analysis and the data analysis
is based on the remaining 755 patients. The mean age of patients is 61.0 years (standard deviation,
9.5 years). 375 patients are in the placebo group and 380 are in the treatment group. About 65.8% of
patients are male and the average disease duration is 1.1 years (standard deviation, 1.1 years). Before
the end of the study, some patients (207 in placebo and 146 in treatment) reached a pre-defined level
of functional disability, which is considered to be a terminal event because these patients would then
initiate symptomatic treatment of levodopa, which can ameliorate the clinical outcomes. Figure 1
displays the mean UPDRS measurements over time for DATATOP patients with follow-up time less
than 6 months (96 patients, solid line), 6-12 months (215 patients, dotted line), and more than 12
months (444 patients, dashed line). Figure 1 suggests that patients with shorter follow-up had higher
UPDRS measurements, manifesting the strong correlation between the PD symptoms and terminal
event. Similar patterns are observed in HY and SEADL measurements. Such a dependent terminal
event time, if not properly accounted for, may lead to biased estimates (Henderson et al., 2000).
Because levodopa is associated with possible motor complications (Brooks, 2008), clinicians tend
to provide more targeted interventions to delay their initiation of levodopa use. To this end, in
the context of DATATOP study and similar PD studies, there is an important clinically relevant
prediction question: for a new patient (not included in the DATATOP study) with one or multiple
visits, what are his/her most likely future outcome trajectories (e.g., UPDRS, HY, and SEADL)
and risk of functional disability within the next year, given the outcome histories and the covariate
information? These important predictive measures are highly relevant for PD patient targeting,
management, prognosis, and treatment selection. In this article, we propose to develop a Bayesian
personalized prediction approach based on a joint modeling framework consisting of a semiparametric
multilevel latent trait model (MLLTM) for multivariate longitudinal outcomes and a survival model
for the event time data (time to functional disability).
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Figure 1: Mean UPDRS values over time for DATATOP patients with follow-up time less than 6
months (solid line), 6-12 months (dotted line), and more than 12 months (dashed line).
3 Methods
3.1 Joint modeling framework
In the context of clinical trials with multiple outcomes, the data structure is often of the type
{yik(tij), ti, δi}, where yik(tij) is the kth (k = 1, . . . , K) outcome, which can be binary, ordinal, or
continuous, for patient i (i = 1, . . . , I) at visit j (j = 1, . . . , Ji) recorded at time tij from the study
onset, ti = min(T
∗
i , Ci) is the observed event time to functional disability, as the minimum between
the true event time T ∗i and the censoring time Ci which are assumed to be independent of T
∗
i , and
δi is the censoring indicator (1 if the event is observed, and 0 otherwise). We propose to use a
semiparametric multilevel latent trait model (MLLTM) for the multiple longitudinal outcomes and
a survival model for the event time.
To start building the semiparametric MLLTM framework, we assume that there is a latent variable
representing the underlying disease severity score and denote it as θi(t) for patient i at time t with
a higher value for more severe status. We introduce the first level model for continuous outcomes,
yik(t) = ak + bkθi(t) + εik(t), (1)
where ak and bk (positive) are the outcome-specific parameters, and the random errors εik(t) ∼
N(0, σ2εk). Note that ak = E[yik(t)|θi(t) = 0] is the mean of the kth outcome if the disease severity
score is 0 and bk is the expected increase in the kth outcome for one unit increase in the disease
severity score. The parameter bk also plays the role of bringing up the disease severity score to the
scale of the kth outcome. The models for outcomes that are binary (e.g., the presence of adverse
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events) and ordinal (e.g., HY and SEADL) are as follows (Fox, 2005):
logit
{
p(yik(t) = 1|θi(t))} = ak + bkθi(t)
logit
{
p(yik(t) ≤ l|θi(t))
}
= akl − bkθi(t), (2)
where l = 1, 2, . . . , nk − 1 is the lth level of the kth ordinal variable with nk levels. Note that the
negative sign for bk in the ordinal outcome model is to ensure that worse disease severity (higher
θi(t)) is associated with a more severe outcome (higher yik(t)). Interpretation of parameters is
similar for continuous outcomes, except that modeling is on the log-odds, not the native scale, of
the data. We have selected logit link function in model (2), while other link functions (e.g., probit
and complementary log-log) can be adopted. A major feature of models (1) and (2) is that they all
incorporate θi(t) and explicitly combine longitudinal information from all outcomes.
To model the dependence of severity score θi(t) on covariates, we propose the second level semi-
parametric model
θi(t) =X i(t)β +Zi(t)ui + V R(t)ζ, (3)
where vectors X i(t) and Zi(t) are p and q dimensional covariates corresponding to fixed and random
effects, respectively. They can include covariates of interest such as treatment and time. To allow
additional flexibility and smoothness in modeling the effects of some covariates, we adopt a smooth
time function V R(t)ζ =
∑R
r=1 ζr(t − κr)+ using the truncated power series spline basis expansion
V R(t) = {(t− κ1)+, . . . , (t− κR)+}, where κ = {κ1, . . . , κR} are the knots, and (t− κr)+ = t− κr if
t > κr and 0 otherwise. Following Ruppert (2002), we consider a large number of knots (typically 5
to 20) that can ensure the desired flexibility and we select the knot location to have sufficient subjects
between adjacent knots. To avoid overfitting, we explicitly introduce smoothing by assuming that
ζ = (ζ1, . . . , ζR)
′ ∼ N(0, σ2ζI)(Ruppert et al., 2003; Crainiceanu et al., 2005). The choice of knots
is important to obtain a well fitted model and should be selected with caution to avoid overfitting.
Several approaches of automatic knot selection based on stepwise model selection have been proposed
(Friedman & Silverman, 1989; Stone et al., 1997; Denison et al., 1998; DiMatteo et al., 2001). Wand
(2000) gives a good review and comparison of some of these approaches. Penalizing the spline
coefficients to constrain their influence also helps to avoid overfitting (Ruppert et al., 2003), as in
our model. Moreover, in clinical studies with same scheduled follow-up visits, the frequency of
study visits needs to be accounted for in the selection of knots. For the ease of illustration, we
include the nonparametric smooth function for the time variable, although our model can be extended
to accommodate more nonparametric smooth functions. The vector ui = (ui1, . . . , uiq)
′ contains
the random effects for patient i’s latent disease severity score and it is distributed as N(0,Σ).
Equations (1), (2) and (3) consist of the semiparametric MLLTM model, which provides a nature
framework for defining the overall effects of treatment and other covariates. Indeed, if θi(t) =
β0+β1xi+β2t+β3xit+
∑R
r=1 ζr(t−κr)++ui0+ui1t, where xi is treatment indicator (1 if treatment
and 0 otherwise), then β1 is the main treatment effect and β3 is the time-dependent treatment effect.
In this context, the null hypothesis of no overall treatment effect is H0 : β1 = β3 = 0. Because
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the number of outcomes (K) has been reduced to one latent disease severity score, models are quite
parsimonious in terms of number of random effects, which improves computational feasibility and
model interpretability.
Because the semiparametric MLLTM model is over-parameterized, additional constraints are
required to make it identifiable. Specifically, we set ak1 = 0 and bk = 1 for one ordinal outcome.
For the ordinal outcome k with nk categories, the order constraint ak1 < . . . < akl < . . . < aknk−1
must be satisfied, and the probability of being in a particular category is p(Yik(t) = l) = p(Yik(t) ≤
l|θi(t))− p(Yik(t) ≤ l − 1|θi(t)). With these assumptions, the conditional log-likelihood of observing
the patient i data {yik(tij)} given ui and ζ is ly(Θy;yi,ui, ζ) =
∑Ji
j=1
∑K
k=1 log p(yik(tij)|ui, ζ). For
notational convenience, we let a = (a′1, . . . ,a
′
k, . . . ,a
′
K)
′, with ak being numeric for binary and
continuous outcomes and ak = (ak1, . . . , aknk−1)
′ for ordinal outcomes. We let b = (b1, . . . , bK)
′
and yi(t) = {yik(t), k = 1, . . . , K}
′ be the vector of measurements for patient i at time t and let
yi = {yi(tij), j = 1, . . . , Ji} be the outcome vector across Ji visit times. The parameter vector for
the longitudinal process is Θy = (a
′, b′,β′,Σ, σεk , σζ)
′.
To model the survival process, we use the proportional hazard model
hi(t) = h0(t) exp{W iγ + νθi(t)}, (4)
where γ is the coefficient for time-independent covariatesW i and h0(·) is the baseline hazard function.
Some covariates in W i can overlap with vector X i(t) in model (3). Ibrahim et al. (2010) gave an
excellent explanation of the coefficients for those overlapped covariates. In the current context, if
we denote βo and γo as the coefficients for the overlapped covariates in vectors X i(t) and W i,
respectively, we have: (1) βo is the covariate effect on the longitudinal latent variable; (2) γo is the
direct covariate effect on the time to event; (3) νβo+γo is the overall covariate effect on the time to
event. The association parameter ν quantifies the strength of correlation between the latent variable
θi(t) and the hazard for a terminal event at the same time point (refer to as ‘Model 1: shared latent
variable model’). Specifically, a value of ν = 0 indicates that there is no association between the
latent variable and the event time while a positive association parameter ν implies that patients with
worse disease severity tend to have a terminal event earlier, e.g., a value of ν = 0.5 indicates that the
hazard rate of having the terminal event increases by 65% (i.e., exp(0.5)− 1) for every unit increase
in the latent variable. For prediction of subject-specific survival probabilities, a specified and smooth
baseline hazard function is desired. To this end, we again adopt a truncated power series spline basis
expansion h0(t) = exp{η0 + η1t +
∑R
r=1 ξr(t − κr)+} and assume ξ = (ξ1, . . . , ξR)
′ ∼ N(0, σ2ξI) to
introduce smoothing. The knot locations can be the same or different from those in equation (3).
In equation (4), different formulations can be used to postulate how the risk for a terminal event
depends on the unobserved disease severity score at time t. For example, one can add to equation (4)
a time-dependent slope θ′i(t), so that the risk depends on both the current severity score and the
slope of the severity trajectory at time t (refer to as ‘Model 2: time-dependent slope model’):
hi(t) = h0(t) exp{W iγ + ν1θi(t) + ν2θ
′
i(t)}. (5)
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Alternatively, one can consider the standard formulations of joint models that include only the
random effects in the Cox model (refer to as ‘Model 3: shared random effects model’):
hi(t) = h0(t) exp{W iγ + ν
′ui}. (6)
A good summary of these various formulations in the joint modeling framework can be found in
Rizopoulos et al. (2014) and Yang et al. (2016).
The log-likelihood of observing event outcome ti and δi for patient i is
ls(Θs; ti, δi,ui, ζ, ξ) = log{hi(ti)
δiSi(ti)}, where the survival function Si(ti) = exp{−
∫ ti
0
hi(s)ds} and
the parameter vector for the survival process isΘs = (γ
′, ν, η0, η1, σξ)
′. Note that the truncated power
series spline basis expansion in modeling the smooth time function in equation (3) and in modeling
the baseline hazard function is linear function of time, which results in tractable integration in the
survival function Si(ti), and consequently, significant gain in computing efficiency. Conditional on
the random effect vector ui, yi is assumed to be independent of ti. The penalized log-likelihood of
the joint model for patient i given random effects ui and smoothing parameters σζ , σξ is
l(Θ, ζ, ξ; ·) = ly(Θy;yi,ui, ζ) + ls(Θs; ti, δi,ui, ζ, ξ)−
1
σ2ζ
ζ′ζ −
1
σ2ξ
ξ′ξ, (7)
where the unknown parameter vector Θ = (Θ′y,Θ
′
s)
′.
3.2 Bayesian inference
To infer the unknown parameter vector Θ, we use Bayesian inference based on Markov chain Monte
Carlo (MCMC) posterior simulations. The fully Bayesian inference has many advantages. First,
MCMC algorithms can be used to estimate exact posterior distributions of the parameters, while
likelihood-based estimation only produces a point estimate of the parameters, with asymptotic stan-
dard errors (Dunson, 2007). Second, Bayesian inference provides better performance in small samples
compared to likelihood-based estimation (Lee & Song, 2004). In addition, it is more straightforward
to deal with more complicated models using Bayesian inference via MCMC. We use vague priors on
all elements in Θ. Specifically, the prior distributions of parameters ν, η0, η1, and all elements in
vectors β and γ are N(0, 100). We use the prior distribution bk ∼ Uniform(0, 10), k = 2, . . . , K, to
ensure positivity. The prior distribution for the difficulty parameter ak of the continuous outcomes
is ak ∼ N(0, 100). To obtain the prior distributions for the threshold parameters of ordinal outcome
k, we let ak1 ∼ N(0, 100), and akl = ak,l−1 + ∆l for l = 2, . . . , nk − 1, with ∆l ∼ N(0, 100)I(0, ),
i.e., normal distribution left truncated at 0. We use the prior distribution Uniform[−1, 1] for all
the correlation coefficients ρ in the covariance matrix Σ, and Inverse-Gamma(0.01, 0.01) for all vari-
ance parameters. We have investigated other selections of vague prior distributions with various
hyper-parameters and obtained very similar results.
The posterior samples are obtained from the full conditional of each unknown parameter using
Hamiltonian Monte Carlo (HMC) (Duane et al., 1987) and No-U-Turn Sampler (NUTS, a variant of
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HMC) (Hoffman & Gelman, 2014). Compared with the Metropolis-Hastings algorithm, HMC and
NUTS reduce the correlation between successive sampled states by using a Hamiltonian evolution
between states and by targeting states with a higher acceptance criteria than the observed probability
distribution, leading to faster convergence to the target distribution. Both HMC and NUTS samplers
are implemented in Stan, which is a probabilistic programming language implementing statistical
inference. The model fitting is performed in Stan (version 2.14.0) (Stan Development Team, 2016)
by specifying the full likelihood function and the prior distributions of all unknown parameters.
For large dataset, Stan may be more efficient than BUGS language (Lunn et al., 2000) in achieving
faster convergence and requiring smaller number of samples (Hoffman & Gelman, 2014). To monitor
Markov chain convergence, we use the history plots and view the absence of apparent trends in the
plot as evidence of convergence. In addition, we use the Gelman-Rubin diagnostic to ensure the
scale reduction R̂ of all parameters are smaller than 1.1 as well as a suite of convergence diagnosis
criteria to ensure convergence (Gelman et al., 2013). After fitting the model to the training dataset
(the dataset used to build the model) using Bayesian approaches via MCMC, we obtain M (e.g.,
M = 2, 000 after burn-in) samples for the parameter vector Θ0 = (Θ
′, ζ ′, ξ′)′. To facilitate easy
reading and implementation of the proposed joint model, a Stan code has been posted in the 6. Note
that Stan requires variable types to be declared prior to modeling. The declaration of matrix Σ as
a covariance matrix ensures it to be positive-definite by rejecting the samples that cannot produce
positive-definite matrix Σ. Please refer to the Stan code in the 6 for details.
3.3 Dynamic prediction framework
We illustrate how to make prediction for a new subject N , based on the available outcome histories
y
{t}
N = {yN(tNj); 0 ≤ tNj ≤ t} and the covariate history X
{t}
N = {XN(tNj),ZN(tNj),WN ; 0 ≤ tNj ≤
t} up to time t, and δN = 0 (no event). We want to obtain two personalized predictive measures:
the longitudinal trajectories yNk(t
′), for k = 1, . . . , K, at a future time point t′ > t (e.g., t′ = t+∆t),
and the probability of functional disability before time t′, denoted by piN(t
′|t) = p(T ∗N ≤ t
′|T ∗N >
t,y
{t}
N ,X
{t}
N ). To do this, the key step is to obtain samples for patient N ’s random effects vector uN
from its posterior distribution p(uN |T
∗
N > t,y
{t}
N ,Θ0). Specifically, conditional on the mth posterior
sample Θ
(m)
0 , we draw the mth sample of the random effects vector uN from its posterior distribution
p(uN |T
∗
N > t,y
{t}
N ,Θ
(m)
0 ) =
p(y
{t}
N , T
∗
N > t,uN |Θ
(m)
0 )
p(y
{t}
N , T
∗
N > t|Θ
(m)
0 )
∝ p(y
{t}
N , T
∗
N > t,uN |Θ
(m)
0 )
= p(y
{t}
N |uN ,Θ
(m)
0 )p(T
∗
N > t|uN ,Θ
(m)
0 )p(uN |Θ
(m)
0 ),
where the first equality is from Bayes theorem.
For each of Θ
(m)
0 , m = 1, . . . ,M , we use adaptive rejection Metropolis sampling (Gilks et al.,
1995) to draw 50 samples of random effects vector uN and retain the final sample. This process is
repeated for theM saved values of Θ0. Suppose that patient N does not develop functional disability
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by time t′, then the outcome histories are updated to y
{t′}
N . We can dynamically update the posterior
distribution to p(uN |T
∗
N > t
′,y
{t′}
N ,Θ
(m)
0 ), draw new samples, and obtain the updated predictions.
With the M samples for patient N ’s random effects vector uN , predictions can be obtained by
simply plugging in realizations of the parameter vector and random effects vector {Θ
(m)
0 ,u
(m)
N , m =
1, . . . ,M}. For example, themth sample of continuous outcome yNk(t
′) is obtained from equations (1)
and (3):
y
(m)
Nk (t
′) = a
(m)
k + b
(m)
k
{
XN(t
′)β(m) +ZN(t
′)u
(m)
N + V R(t
′)ζ(m)
}
+ ε
(m)
Nk (t
′),
where the random errors ε
(m)
Nk (t
′) ∼ N(0, σ
2(m)
εk ), and each parameter is replaced by the corresponding
element in the mth sample {Θ
(m)
0 ,u
(m)
N }.
Similarly, the mth sample of ordinal outcome yNk(t
′) = l with l = 1, 2, . . . , nk is
logit
{
p
(
y
(m)
Nk (t
′) ≤ l
)}
= a
(m)
kl − b
(m)
k
{
XN(t
′)β(m) +ZN (t
′)u
(m)
N + V R(t
′)ζ(m)
}
.
The probability of being in category l is p
(
y
(m)
ik (t
′) = l
)
= p
(
y
(m)
ik (t
′) ≤ l
)
− p
(
y
(m)
ik (t
′) ≤ l − 1
)
. The
mth sample of the hazard of patient i at time t′ is
h
(m)
N (t
′|u
(m)
N ) = h
(m)
0 (t
′) exp
{
WNγ
(m) + ν(m)
[
XN(t
′)β(m) +ZN(t
′)u
(m)
N + V R(t
′)ζ(m)
]}
.
Thus, the conditional probability of functional disability before time t′ is
piN(t
′|t) =
∫
p(T ∗N ≤ t
′|T ∗N > t,y
{t}
N ,X
{t}
N ,uN )p(uN |T
∗
N > t,y
{t}
N ,X
{t}
N )duN
≈
1
M
M∑
m=1
p
(
T ∗N ≤ t
′|T ∗N > t,y
{t}
N ,X
{t}
N ,u
(m)
N
)
=
1
M
M∑
m=1
{
1−
p(T ∗N > t
′|y
{t}
N ,X
{t}
N ,u
(m)
N )
p(T ∗N > t|y
{t}
N ,X
{t}
N ,u
(m)
N )
}
=
1
M
M∑
m=1
{
1− exp
(
−
∫ t′
t
h
(m)
N (s|u
(m)
N )ds
)}
,
where the integration with respect to uN in the first equality is approximated using Monte Carlo
method. Note that the truncated power series spline basis expansion in modeling the smooth time
function in equation (3) and in modeling the baseline hazard function results in tractable integration
not only in the survival function SN(tN ), but also in the integration of hazard function in the last
equality. All prediction results can then be obtained by calculating simple summaries (e.g., mean,
variance, quantiles) of the posterior distributions of M samples
{
y
(m)
Nk (t
′), m = 1, . . . ,M
}
. Note that
although it may take a few hours to obtain enough posterior samples for the parameter vector Θ0,
it only takes a few seconds to obtain the prediction results for a new subject. Hence, the dynamic
prediction framework and the web-based calculator (detailed in Section 4) can provide instantaneous
supplemental information for PD clinicians to monitor disease progression.
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3.4 Assessing predictive performance
It is essential to assess the performance of the proposed predictive measures. Here, we focus on
the probability pi(t′|t). Specifically, we assess the discrimination (how well the models discriminate
between patients who had the event from patients who did not) using the receiver operating charac-
teristic (ROC) curve and the area under the ROC curves (AUC) and assess the validation (how well
the models predict the observed data) using the expected Brier score (BS).
3.4.1 Area under the ROC curves
Following the notation in Section 3.3, for any given cut point c ∈ (0, 1), the time-dependent sen-
sitivity and specificity are defined as sensitivity(c, t, t′) : P {pii(t
′|t) > c|Ni(t, t
′) = 1, T ∗i > t} and
specificity(c, t, t′) : P {pii(t
′|t) ≤ c|Ni(t, t
′) = 0, T ∗i > t}, respectively, where Ni(t, t
′) = I(t < T ∗i ≤ t
′),
indicating whether there is an event (case) or no event (control) observed for subject i during the time
interval (t, t′]. In the absence of censoring, sensitivity and specificity can be simply estimated from
the empirical distribution of the predicted risk among either cases or controls. To handle censored
event times, Li et al. (2016) proposed an estimator for the sensitivity and specificity based on the
predictive distribution of the censored survival time:
P̂ {pii(t
′|t) > c|Ni(t, t
′) = 1, T ∗i > t} =
∑n
i=1 Ŵi(t, t
′)I{pii(t
′|t) > c}∑n
i=1 Ŵi(t, t
′)
(8)
P̂ {pii(t
′|t) ≤ c|Ni(t, t
′) = 0, T ∗i > t} =
∑n
i=1[1− Ŵi(t, t
′)]I{pii(t
′|t) ≤ c}∑n
i=1[1− Ŵi(t, t
′)]
,
where Ŵi(t, t
′) is the weight to account for censoring and it is defined as
Ŵi(t, t
′) = I(t < ti ≤ t
′)δi + I(t < ti ≤ t
′)(1− δi)P{T
∗
i < t
′|T ∗i ≥ ti, pii(t
′|t)}
= I(t < ti ≤ t
′)δi + I(t < ti ≤ t
′)(1− δi)
[
1−
P{T ∗i ≥ t
′|pii(t
′|t)}
P{T ∗i ≥ ti|pii(t
′|t)}
]
.
Note that the subjects who have the survival event before time t (i.e., ti < t) have their estimated
weight Ŵi(t, t
′) = 0 and thus they play no role in equation (8). The conditional survival distribution
P{T ∗i ≥ t˜|pii(t
′|t)}, where t˜ can be either t′ or ti, can be estimated using kernel weighted Kaplan-
Meier method with a bandwidth d, which can be easily implemented in standard survival analysis
software accommodating weighted data:
P{T ∗i ≥ t˜|pii(t
′|t)} =
∏
s∈Ω,s≤t˜
[
1−
∑
i′ 6=iKd{pii′(t
′|t), pii(t
′|t)}I(Ti′ = s)δi′∑
i′ 6=iKd{pii′(t
′|t), pii(t′|t)}I(Ti′ ≥ s)
]
,
where Ω is the set of distinct ti’s with δi = 1 and Kd is the kernel function, e.g., uniform and Gaussian
kernels. Specifically, we use uniform kernel in this article.
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With the estimation of sensitivity and specificity, the time-dependent ROC curve can be con-
structed for all possible cut points c ∈ (0, 1) and the corresponding time-dependent AUC(t, t′) can
be estimated using standard numerical integration methods such as Simpson’s rule.
3.4.2 Dynamic Brier score
The Brier score (BS) developed in survival models can be extended to joint models for prediction
validation (Se`ne et al., 2016; Proust-Lima et al., 2014). The dynamic expected BS is defined as
E[(D(t′|t)− pi(t′|t))2], where the observed failure status D(t′|t) equals to 1 if the subject experiences
the terminal event within the time interval (t, t′] and 0 if the subject is event free until t′. An
estimator of BS is
B̂S(t, t′) =
1
Nt
Nt∑
i=1
Ĝi(t, t
′) (Di(t, t
′)− pii(t
′|t))
2
,
where Nt is the number of subjects at risk at time t, and the weight Ĝi(t, t
′) = I(ti>t
′)
Sˆ0(t′)/Sˆ0(t)
+ I(t<ti≤t
′)δi
Sˆ0(ti)/Sˆ0(t)
is to account for censoring with Sˆ0 denoting the Kaplan-Meier estimate (Se`ne et al., 2016).
AUC and BS complement each other by assessing different aspects of the prediction. AUC has a
simple interpretation as a concordance index, while BS accounts for the bias between the predicted
and true risks. In general, AUC = 1 indicates perfect discrimination and AUC = 0.5 means no better
than random guess, while BS = 0 indicates perfect prediction and BS = 0.25 means no better than
random guess. Blanche et al. (2015) provides excellent illustration of AUC and BS.
4 Application to the DATATOP study
In this section, we apply the proposed joint model and prediction process to the motivating DATATOP
study. For all results in this section, we run two parallel MCMC chains with overdispersed initial
values and run each chain for 2, 000 iterations. The first 1, 000 iterations are discarded as burn-in and
the inference is based on the remaining 1, 000 iterations from each chain. Good mixing properties of
the MCMC chains for all model parameters are observed in the trace plots. The scale reduction R̂
of all parameters are smaller than 1.1.
In order to validate the prediction and compare the performance of candidate models, we conduct
a 5-fold cross-validation, where 4 partitions of the data are used to train the model and the left-
out partition is used for validation and model selection. Then we fit the final selected model to
the whole dataset, except that 2 patients are set aside for subject-specific prediction purpose. The
covariates of interest included in equation (3) are baseline disease duration, baseline age, treatment
(active deprenyl only), time, and the interaction term of treatment and time. We allow a flexible
and smooth disease progression along time by using penalized truncated power series splines with 7
knots at the location κ = (1.2, 3, 6, 9, 12, 15, 18) in months, to ensure sufficient patients within each
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interval. Specifically, euqation (3) is
θi(tij) = β0 + β1durationi + β2agei + β3trti + β4tij
+β5(trti × tij) +
7∑
r=1
ζr(tij − κr)+ + ui0 + ui1tij ,
where the random effects (ui0, ui1)
′ ∼ N2(0,Σ) withΣ = {(σ
2
1, ρσ1σ2), (ρσ1σ2, σ
2
2)} and ζ ∼ N(0, σ
2
ζI)
to avoid overfitting.
For the survival part, three different formulations are considered as discussed in Section 3.1.
For instance, the shared latent variable model (Model 1) is hi(t) = h0(t) exp(γ1durationi + γ2agei +
γ3trti+νθi(t)). The proposed time-dependent slope model (Model 2) and shared random effects model
(Model 3) can be obtained by replacing νθi(t) with ν1θi(t)+ν2θ
′
i(t) and ν
′ui, respectively. The baseline
hazard h0(t) is similarly approximated by penalized splines h0(t) = exp{η0+ η1t+
∑7
r=1 ξr(t− κr)+}
and ξ ∼ N(0, σ2ξI). In addition, we compared the proposed model with two standard predictive
models for time to event data, (1) a widely used univariate joint model (refer to as Model JM), where
the continuous UPDRS is used as the longitudinal outcome regressing on same covariates of interest
and the survival part is constructed in the same structure, and (2) a naive Cox model adjusted for
time-independent covariates including all baseline characteristics as well as UPDRS, HY and SEADL
scores.
We compare the performance of all candidate models in terms of discrimination and validation
using 5-fold cross-validation and present AUC and BS score in Table 1 and Web Table S1. All of the
three formulations of the proposed MLLTM joint model outperform the univariate Model JM (except
AUC(t = 3, t′ = 9)) and naive Cox model with larger AUC and smaller BS in most of the scenarios,
suggesting that the MLLTM model accounting for multivariate longitudinal outcomes are preferable
in terms of prediction. The three formulations have very similar performance with close AUC and
BS. Model 1 is selected as our final model, because it leads to a straightforward interpretation of
the overall covariate effect described in Section 3.1 and it is more intuitive to use the trajectory of
latent variable θi(t) to predict the time to event as in Model 1, instead of using time-dependent slope
θ′i(t) or random effects ui as in Models 2 and 3. The results also suggest that AUC increases by
using more follow up measurements, e.g., in Model 1, conditional on the the measurement history
up to month 3 (i.e., t = 3), when t′ = 15, AUC(t = 3, t′ = 15) = 0.744, while AUC increase
to AUC(t = 12, t′ = 15) = 0.766, indicating that conditional on the measurement history up to
month 12, our model has 0.766 probabilities to correctly assign higher probability of functional
disability by month 15 to more severe patients (who had functional disability earlier) than less severe
patients (who had functional disability later). Meanwhile, BS decreases from BS(3, 15) = 0.216 to
BS(12, 15) = 0.108, i.e., the mean square error of prediction decreases from 0.216 to 0.108, suggesting
better prediction in terms of validation.
Parameter estimates based on Model 1 are presented in Table 2 and Web Table S2 (outcome-
specific parameters only). To illustrate the subject-specific predictions, we set aside two patients
from the DATATOP study and predict their longitudinal trajectories as well as the probability of
13
Table 1: Area under the ROC curve and Brier score (BS) for the DATATOP study.
t t′
Model 1 Model 2 Model 3 Model JM Cox
AUC BS AUC BS AUC BS AUC BS AUC BS
3 9 0.754 0.136 0.759 0.138 0.761 0.139 0.757 0.140 0.736 0.139
12 0.744 0.204 0.744 0.200 0.744 0.200 0.739 0.203 0.725 0.203
15 0.744 0.216 0.742 0.212 0.744 0.211 0.726 0.218 0.719 0.212
18 0.775 0.171 0.766 0.163 0.772 0.167 0.728 0.186 0.720 0.185
6 9 0.789 0.078 0.806 0.078 0.806 0.078 0.770 0.081 0.721 0.094
12 0.764 0.159 0.778 0.154 0.775 0.154 0.732 0.164 0.705 0.173
15 0.763 0.183 0.771 0.178 0.771 0.178 0.725 0.194 0.697 0.194
18 0.786 0.158 0.773 0.154 0.769 0.159 0.726 0.175 0.701 0.175
12 15 0.766 0.108 0.787 0.103 0.782 0.102 0.695 0.124 0.647 0.155
18 0.758 0.149 0.739 0.147 0.723 0.153 0.700 0.161 0.663 0.163
functional disability at a clinically relevant future time point, conditional on their available measure-
ments. A more severe Patient 169 with clinically worse longitudinal measures and earlier development
of functional disability as well as a less severe Patient 718 are selected. Patient 169 had 8 visits with
mean UPDRS 42.6 (SD 7.7), median HY 2, median SEADL 80, and developed functional disability
at month 16. In contrast, Patient 718 had 9 visits with mean UPDRS 15.6 (SD 3.1), median HY 1,
median SEADL 95, and was censored at month 21. Figure 2 displays the predicted UPDRS trajec-
tories for these two patients, based on different amounts of data. When only baseline measurements
are used for prediction, the predicted UPDRS trajectory is biased with wide uncertainty band. For
example, Patient 169 had a relatively low baseline UPDRS value of 33 and our model based only
on baseline measurements tends to underpredict the future UPDRS trajectory (ti = 0, the first plot
in upper panels). However, Patient 169’s higher UPDRS values of 41 and 40 at months 1 and 3,
respectively, subsequently shift up the prediction and tend to overpredict the future trajectory (ti = 3
months, the second plot in upper panels). By using more follow-up data, predictions are closer to
the true observed values and the 95% uncertainty band is narrower (ti = 6 or 12 months, the last
two plots in upper panels). Patient 169’s predicted UPDRS values after 12 months are above 40 and
increase rapidly, indicating a higher risk of functional disability in the near future. In comparison,
the predicted UPDRS values for Patient 718 are relatively stable because his/her observed UPDRS
values are relatively stable.
The predicted probability being in each category for outcomes HY and SEADL are presented
in Web Figures S1 and S2, respectively. Please refer to the 6 for the interpretation. Besides the
predictions of longitudinal trajectories, it is more of clinical interest for patients and clinicians to
know the probability of functional disability before time t′ > t: pii(t
′|t), conditional on the patient’s
14
0
20
40
60
80
10
0
after baseline visit
Months
UP
DR
S
0 3 6 9 12 15 18 21 24
0
20
40
60
80
10
0
after 3 month visit
Months
UP
DR
S
0 3 6 9 12 15 18 21 24
0
20
40
60
80
10
0
after 6 month visit
Months
UP
DR
S
0 3 6 9 12 15 18 21 24
0
20
40
60
80
10
0
after 12 month visit
Months
UP
DR
S
0 3 6 9 12 15 18 21 24
0
20
40
60
80
10
0
after baseline visit
Months
UP
DR
S
0 3 6 9 12 15 18 21 24
0
20
40
60
80
10
0
after 3 month visit
Months
UP
DR
S
0 3 6 9 12 15 18 21 24
0
20
40
60
80
10
0
after 6 month visit
Months
UP
DR
S
0 3 6 9 12 15 18 21 24
0
20
40
60
80
10
0
after 12 month visit
Months
UP
DR
S
0 3 6 9 12 15 18 21 24
Figure 2: Predicted UPDRS for Patient 169 (upper panels) and Patient 718 (lower panels). Solid
line is the mean of 2000 MCMC samples. Dashed lines are the 2.5% and 97.5% percentiles range of
the 2000 MCMC samples. The dotted vertical line represents the time of prediction t.
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Table 2: Parameter estimates for the DATATOP study from Model 1.
Mean SD 95% CI
For latent disease severity
Int −0.738 0.338 −1.385 −0.081
Duration (months) 0.021 0.004 0.014 0.028
Age (years) 0.024 0.005 0.014 0.035
Trt (deprenyl) −0.108 0.099 −0.304 0.099
Time (months) 0.021 0.025 −0.028 0.070
Trt × Time −0.089 0.010 −0.109 −0.071
ρ 0.310 0.044 0.226 0.393
σ1 1.328 0.051 1.230 1.430
σ2 0.116 0.006 0.104 0.128
σε 5.081 0.074 4.933 5.226
For survival process
Duration (months) −0.009 0.004 −0.017 −0.002
Age (years) −0.034 0.006 −0.045 −0.024
Trt (deprenyl) −0.608 0.118 −0.846 −0.375
ν 0.692 0.039 0.618 0.769
longitudinal profiles up to time t and the fact that he/she did not have functional disability up to
time t. The predicted probabilities for Patients 169 and 718 based on various amount of data are
presented in Figure 3. A similar pattern is that the prediction becomes more accurate if more data
are used. With such predictions, clinicians are able to precisely track the health condition of each
patient and make better informed decisions individually. For example, based on the first 12 months’
data, for Patient 169, the predicted probabilities in the next 3, 6, 9 and 12 months are 0.21, 0.46,
0.78 and 0.97 (the last plot of upper panels), while for Patient 718, the probabilities are 0.02, 0.06,
0.13 and 0.30 (the last plot of lower panels). Patient 169 has higher risk of functional disability in
the next few months and clinicians may consider more invasive treatments to control the disease
symptoms before the functional disability is developed.
To facilitate the personalized dynamic predictions in clinical setting, we develop a web-based
calculator available at https://kingjue.shinyapps.io/dynPred_PD. A screenshot of the user in-
terface is presented in Web Figure S3. The calculator requires as input the PD patients’ baseline
characteristics and their longitudinal outcome values up to the present time. The online calculator
will then produce time-dependent predictions of future health outcomes trajectories and the proba-
bility of functional disability, in addition to the 95% uncertainty bands. Moreover, additional data
generated from more follow-up visits can be input to obtain updated predictions. The calculator is a
user friendly and easily accessible tool to provide clinicians with dynamically-updated patient-specific
future health outcome trajectories, risk predictions, and the associated uncertainty. Such a transla-
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Figure 3: Predicted conditional failure probability for Patient 169 (upper panels) and Patient 718
(lower panels). Solid line is the mean of 2000 MCMC samples. Dashed lines are the 2.5% and 97.5%
percentiles range of the MCMC samples.
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tional tool would be relevant both for clinicians to make informed decisions on therapy selection and
for patients to better manage risks.
5 Simulation studies
In this section, we conduct an extensive simulation study to investigate the prediction performance
of the probability pi(t′|t) using the proposed Model 1. We generate 200 datasets with samples size
n = 800 subjects and six visits, i.e., baseline and five follow-up visits (Ji = 6), with the time vector
ti = (ti1, ti2, . . . , ti6)
′ = (0, 3, 6, 12, 18, 24). The simulated data structure is similar to the motivating
DATATOP study, and it includes one continuous outcome and two ordinal outcomes (each with 7
categories).
Data are generated from the following models: θi(tij) = β0 + β1xi1 + β2tij + β3xi1tij + ui0 + ui1tij
and hi(t) = h0 exp{γxi2 + νθi(t)}, where the longitudinal and survival submodels share the latent
variable as in proposed Model 1. Covariate xi1 takes value 0 or 1 each with probability 0.5 to mimic
treatment assignment and covariate xi2 is randomly sampled integer from 30 to 80 to mimic age. We
set coefficients β = (β0, β1, β2, β3)
′ = (−1,−0.2, 0.8,−0.2)′, γ = −0.12 and ν = 0.75. For simplicity,
baseline hazard is assumed to be constant with h0 = 0.1. Parameters for the continuous outcome
are a1 = 15, b1 = 7 and σε = 5. Parameters for the ordinal outcomes are a2 = (0, 1, 2, 4, 5, 6), a3 =
(−1, 1, 3, 4, 6, 8), b2 = 1 and b3 = 1.2. We assume that random effects vector ui = (ui0, ui1)
′ follows
a multivariate normal distribution N2(0,Σ), where Σ = {(σ
2
1, ρσ1σ2), (ρσ1σ2, σ
2
2)} with σ1 = 1.5,
σ2 = 0.15 and ρ = 0.4. The independent censoring time is sampled from Uniform(10, 24).
From each simulated dataset, we randomly select 600 subjects as the training dataset and set
aside the remaining 200 subjects as the validation dataset. Web Table S3 displays bias (the average
of the posterior means minus the true values), standard deviation (SD, the standard deviation of
the posterior means), coverage probabilities (CP) of 95% equal tail credible intervals (CI), and root
mean squared error (RMSE) of model inference based on the training dataset. The results suggest
that the model fitting based on the training dataset provides parameter estimates with very small
biases and RMSE and the CP being close to the nominal level 0.95. Using MCMC samples from the
fitted model and available measurements up to time t, we make prediction of pii(t
′|t) for each subject
in the validation dataset.
Web Table S4 compares the time-dependent AUC based on various amount of data from Model
1, Model JM and naive Cox model. When 3 or 6 months data are available, Model 1 outperforms
Model JM and Cox with high discriminating capability and higher AUC values above 0.9. In general,
AUC is increasing with more available data, e.g., AUC(3, 12) = 0.920 and AUC(6, 12) = 0.930.
From each of the 200 simulation datasets, we randomly select 20 subjects to plot the bias between
the predicted event probability pi(t′|t) from Model 1 and the true event probability with t′ = 9 (upper
panels) and t′ = 12 (lower panels) in Web Figure S4. When more data are available, bias is decreasing
as more bias is within the region of [−0.2, 0.2]. For example, with only baseline data, 5.8% and 21.7%
of bias for the predictions of pi(t′ = 9|t = 0) and pi(t′ = 12|t = 0), respectively, are outside the range.
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With up to three months’ data, 3.4% and 13.7% of bias for the predictions of pi(t′ = 9|t = 3) and
pi(t′ = 12|t = 3), respectively, are outside the range. With up to six months’ data, the prediction is
precise with only 1.2% and 7.7% of bias for the prediction of pi(t′ = 9|t = 6) and pi(t′ = 12|t = 6),
respectively, being outside the range.
6 Discussion
Multiple longitudinal outcomes are often collected in clinical trials of complex diseases such as Parkin-
son’s disease (PD) to better measure different aspects of disease impairment. However, both the-
oretical and computational complexity in modeling multiple longitudinal outcomes often restrict
researchers to a univariate longitudinal outcome. Without careful analysis of the entire data, pace
of treatment discovery can be dramatically slowed down.
In this article, we first propose a joint model that consists of a semiparametric multilevel latent
trait model (MLLTM) for the multiple longitudinal outcomes by introducing a continuous latent
variable to represent patients’ underlying disease severity, and a survival submodel for the event
time data. The latent variable modeling effectively reduces the number of outcomes and has im-
proved computational feasibility and model interpretability. Next we develop the process of making
personalized dynamic predictions of future outcome trajectories and risks of target event. Extensive
simulation studies suggest that the predictions are accurate with high AUC and small bias. We apply
the method to the motivating DATATOP study. The proposed joint models can efficiently utilize the
multivariate longitudinal outcomes of mixed types, as well as the survival process to make correct
predictions for new subjects. When new measurements are available, predictions can be dynamically
updated and become more accurate and efficient. A web-based calculator is developed as a supple-
mental tool for PD clinicians to monitor their patients’ disease progression. For subjects with high
predicted risk of functional disability in the near future, clinicians may consider more targeted treat-
ment to defer the initiation of levodopa therapy because of its association with motor complications
and notable adverse events (Brooks, 2008). Although the dynamic prediction framework has utilized
only three longitudinal outcomes in the DATATOP study, it can be broadly applied to similar studies
with more longitudinal outcomes.
There are some limitations in our proposed dynamic prediction framework that we will address in
the future study. First, the semiparametric MLLTM submodel assumes a univariate latent variable
(unidimensional assumption), which may be reasonable for small number of outcomes. However, for
large number of longitudinal outcomes, multiple latent variables may be required to fully represent
the true disease severity across different domains impaired by PD. We will develop a multidimen-
sional latent trait model that allows multiple latent variables. Second, Proust-Lima et al. (2013) and
Proust-Lima et al. (2016) proposed a flexible multivariate longitudinal model that can handle mixed
outcomes, including bounded and non-Gaussian continuous outcomes. In contrast, our model (1)
only applied to normally distributed continuous outcomes. In our future research, we would like
to extend the dynamic prediction framework to accommodate more general continuous outcomes
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including bounded and non-Gaussian variables. Third, we have chosen multivariate normal distribu-
tion for the random effects vector because it is flexible in modeling the covariance structure within
and between longitudinal measures of patients and it has meaningful interpretation on correlation.
In fact, misspecification of random effects and residuals has little impact on the parameters that
are not associated with the random effects (Jacqmin-Gadda et al., 2007; Rizopoulos et al., 2008;
McCulloch et al., 2011). The impact of misspecification in the proposed modeling framework war-
rants further investigation. Alternatively, we will relax the normality assumption by considering
Bayesian non-parametric (BNP) framework based on Dirichlet process mixture (Escobar, 1994).
Equation (2) for ordinal outcome requires the proportional odds assumption. Statistical tests to
evaluate this assumption in the traditional ordinal logistic regression have been criticized for having
a tendency to reject the null hypothesis, when the assumption holds (Harrell, 2015). Tests of the pro-
portional odds assumption in the longitudinal latent variable setting are not well established, and the
consequence of violating the assumption is unclear and is worth future examination. Three different
functional forms of joint models that allow various association between the longitudinal and event time
responses are examined and they provide comparable predictions in the DATATOP study. Instead
of selecting a final model in terms of simplicity and easy interpretation, a Bayesian model averaging
(BMA) approach to combine joint models with different association structures (Rizopoulos et al.,
2014) will be investigated in future study. In addition, missed visits and missing covariates exist in
the DATATOP study. In this article, we assume that they are missing at random (MAR). However,
the missing data issue becomes more complicated in prediction model framework because it can im-
pact both the model inference (missing data in the training dataset) and dynamic prediction process
(e.g., the new subject only has measurements of UPDRS and HY, but not SEADL). How to address
this issue in the proposed prediction framework is an important direction of future research. More-
over, the online calculator is based on the DATATOP study, which may not represent PD patients
at all stages and from all populations. Nonetheless, the large and carefully studied group of patients
provide an important resource to study the clinical expression of PD. We will continue to improve
the calculator by including more heterogeneous PD patients from different studies.
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Web Supplement
Predicted Probability for Ordinal Outcomes
The predicted probability being in each category for outcome HY is presented in Figure S1. For
example, Patient 169 had HY measurements equal to 2 at all visits. When only the baseline data
are used for prediction (the first plot in upper panels), our model tends to underpredict the disease
progression by assigning sizable probabilities to the less severe HY categories 1 and 1.5 even at
the end of the study, possibly due to low baseline UPDRS value of 33. After month 3 visit (the
second plot in upper panels), our model overpredicts disease progression by assigning abnormally
high probability to the severe category 3, possibly due to higher UPDRS values at months 1 and 3.
However, using the first 6 or 12 months’ data (the last two plots in upper panels), our model has good
fit by correctly assigning the largest posterior probability to HY category 2 for all visits from baseline
to month 12. Moreover, our model properly assigns higher probabilities to more severe categories 2.5
and 3 and negligible probabilities to less severe categories 1 and 1.5 for visits after month 12, due to
the deteriorating UPDRS measure. Similar interpretation can be made to the predicted probability
of being in each SEADL category displayed in Figure S2.
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Table S1: Area under the ROC curve and Brier score (BS) for the DATATOP study.
Model 1 Model 2 Model 3 Model JM Cox
t t
′ AUC (95% CI)
3 9 0.754 0.759 0.761 0.757 0.736
(0.703, 0.802) (0.710, 0.805) (0.713, 0.806) (0.708, 0.802) (0.681, 0.786)
12 0.744 0.744 0.744 0.739 0.725
(0.702, 0.785) (0.702, 0.784) (0.701, 0.785) (0.696, 0.780) (0.682, 0.768)
15 0.744 0.742 0.744 0.726 0.719
(0.702, 0.783) (0.702, 0.780) (0.704, 0.784) (0.682, 0.768) (0.677, 0.760)
18 0.775 0.766 0.772 0.728 0.720
(0.731, 0.819) (0.719, 0.811) (0.723, 0.814) (0.679, 0.772) (0.673, 0.765)
6 9 0.789 0.806 0.806 0.770 0.721
(0.717, 0.851) (0.739, 0.865) (0.740, 0.864) (0.699, 0.834) (0.642, 0.795)
12 0.764 0.778 0.775 0.732 0.705
(0.717, 0.809) (0.731, 0.821) (0.729, 0.820) (0.679, 0.782) (0.651, 0.757)
15 0.763 0.771 0.771 0.725 0.697
(0.716, 0.807) (0.726, 0.814) (0.726, 0.814) (0.678, 0.771) (0.648, 0.743)
18 0.786 0.773 0.769 0.726 0.701
(0.736, 0.832) (0.726, 0.821) (0.720, 0.815) (0.674, 0.776) (0.650, 0.751)
12 15 0.766 0.787 0.782 0.695 0.647
(0.701, 0.828) (0.716, 0.850) (0.710, 0.849) (0.623, 0.768) (0.563, 0.727)
18 0.758 0.739 0.723 0.700 0.663
(0.684, 0.824) (0.671, 0.808) (0.651, 0.790) (0.631, 0.774) (0.592, 0.732)
t t
′ BS (95% CI)
3 9 0.136 0.138 0.139 0.140 0.139
(0.116, 0.155) (0.119, 0.158) (0.119, 0.158) (0.120, 0.159) (0.122, 0.156)
12 0.204 0.200 0.200 0.203 0.203
(0.181, 0.226) (0.180, 0.221) (0.180, 0.220) (0.182, 0.225) (0.184, 0.221)
15 0.216 0.212 0.211 0.218 0.212
(0.192, 0.240) (0.191, 0.234) (0.191, 0.231) (0.195, 0.242) (0.193, 0.232)
18 0.171 0.163 0.167 0.186 0.185
(0.148, 0.196) (0.142, 0.186) (0.147, 0.188) (0.162, 0.211) (0.164, 0.207)
6 9 0.078 0.078 0.078 0.081 0.094
(0.062, 0.095) (0.062, 0.095) (0.062, 0.095) (0.064, 0.099) (0.080, 0.108)
12 0.159 0.154 0.154 0.164 0.173
(0.137, 0.180) (0.134, 0.174) (0.134, 0.174) (0.143, 0.186) (0.155, 0.191)
15 0.183 0.178 0.178 0.194 0.194
(0.160, 0.207) (0.157, 0.199) (0.158, 0.199) (0.171, 0.218) (0.176, 0.214)
18 0.158 0.154 0.159 0.175 0.175
(0.133, 0.183) (0.132, 0.178) (0.138, 0.183) (0.151, 0.201) (0.155, 0.197)
12 15 0.108 0.103 0.102 0.124 0.155
(0.084, 0.133) (0.082, 0.125) (0.080, 0.125) (0.100, 0.150) (0.136, 0.174)
18 0.149 0.147 0.153 0.161 0.163
(0.121, 0.178) (0.121, 0.174) (0.126, 0.179) (0.132, 0.192) (0.139, 0.187)
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Table S2: The outcome-specific parameter estimates for the DATATOP study from Model 1.
Mean SD 95% CI
For UPDRS
a1 17.247 0.341 16.563 17.902
b1 7.624 0.207 7.251 8.035
For HY
a22 0.995 0.036 0.927 1.066
a23 4.087 0.079 3.935 4.243
a24 6.340 0.129 6.087 6.593
For SEADL
a31 −1.462 0.076 −1.610 −1.311
a32 0.583 0.071 0.450 0.720
a33 3.008 0.088 2.838 3.181
a34 3.860 0.096 3.679 4.051
a35 6.020 0.132 5.770 6.283
a36 6.851 0.151 6.558 7.150
a37 8.474 0.203 8.082 8.874
b3 1.270 0.045 1.187 1.363
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Figure S1: Predicted probability of being in each HY category for Patient 169 (upper panels) and
Patient 718 (lower panels). Patient 169 had HY measurements equal to 2 at all 8 visits at months
0, 1, 3, 6, 9, 12, 15, and 16, while Patient 718 had HY measurements equal to 1 at all 9 visits at
months 0, 1, 3, 6, 9, 12, 15, and 18.
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Figure S2: Predicted probability of SEADL to be observed in a given category for Subject 169
(upper panels) and Subject 718 (lower panels). Observed categories of SEADL for Subject 169 in
the 8 follow-up visits are 90, 80, 80, 90, 80, 80, 80, 80 and for Subject 718 in the 9 visits are 95, 95,
95, 95, 90, 95, 95, 95, 95.
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Table S3: Simulation results using the training dataset.
BIAS SD CP RMSE
For the latent disease severity
β0 = −1 0.007 0.114 0.945 0.114
β1 = −0.2 −0.010 0.118 0.970 0.118
β2 = 0.8 0.003 0.022 0.970 0.022
β3 = −0.2 −0.001 0.015 0.940 0.015
σ1 = 1.5 0.009 0.060 0.950 0.060
σ2 = 0.15 0.000 0.007 0.960 0.007
ρ = 0.4 −0.003 0.048 0.935 0.048
For the survival process
γ = −0.12 −0.001 0.007 0.950 0.007
ν = 0.75 0.005 0.044 0.930 0.044
For the first outcome (continuous)
a1 = 15 −0.035 0.471 0.955 0.471
b1 = 7 −0.024 0.183 0.960 0.184
σε = 5 −0.000 0.099 0.960 0.099
For the second outcome (ordinal)
a22 = 1 0.004 0.066 0.925 0.066
a23 = 2 0.014 0.089 0.930 0.090
a24 = 4 0.028 0.124 0.940 0.127
a25 = 5 0.040 0.148 0.920 0.153
a26 = 6 0.038 0.169 0.915 0.173
For the third outcome (ordinal)
a31 = −1 0.004 0.106 0.950 0.106
a32 = 1 0.001 0.110 0.940 0.110
a33 = 3 0.011 0.131 0.950 0.132
a34 = 4 0.012 0.144 0.960 0.144
a35 = 6 0.023 0.194 0.930 0.195
a36 = 8 0.022 0.232 0.950 0.233
b3 = 1.2 −0.000 0.040 0.965 0.040
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Figure S3: A screenshot of the web-based calculator for prediction.
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Table S4: Area under the ROC curve (AUC) for the simulation study.
t t′ Model 1 Model JM Cox True AUC
3 9 0.922 0.909 0.892 0.934
12 0.920 0.908 0.875 0.943
15 0.915 0.903 0.853 0.952
18 0.907 0.896 0.830 0.959
6 9 0.926 0.911 0.883 0.930
12 0.930 0.915 0.868 0.940
15 0.932 0.916 0.847 0.950
18 0.930 0.914 0.825 0.958
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Figure S4: Bias between the predicted failure probability pii(t
′|y
{t}
i ,X
{t}
i ) with true failure probability
when t′ = 9 (upper panels) and t′ = 12 (lower panels) for 20 randomly selected subjects from each
of the 200 simulation datasets.
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Stan code for the simulation study
data {
int<lower=0> N_train; // Number of subjects in training data
int<lower=0> obs; // Number of observations
int subject[obs]; // Subject ID
int<lower=0> K_ordi; // number of ordinal outcomes
real Y_conti[obs];
int<lower=0> Y_ordi[obs, K_ordi];
int<lower=0> n_ordi; // Number of categories for ordinal outcomes
vector[2] zero;
real<lower=0> time[obs];
int<lower=0> treat[obs];
int<lower=0> treat_pts[N_train];
int<lower=0, upper=100> age_pts[N_train];
real tee[N_train]; // Survival time
int<lower=0> event[N_train]; // Censoring indicator
}
parameters {
vector<lower=-10, upper=10>[2] beta0;
vector<lower=-10, upper=10>[2] beta1;
vector[2] U[N_train];
real<lower=0> var1;
real<lower=0> var2;
real<lower=-1, upper=1> rho;
real<lower=0> var_conti;
real gamma;
real nu;
real h0;
real a_conti;
real<lower=0> b_conti;
real a_ordi_temp;
real<lower=0> b_ordi_temp;
vector<lower=0>[n_ordi-2] delta[K_ordi];
}
transformed parameters {
real<lower=0> sig1;
real<lower=0> sig2;
cov_matrix[2] Sigma_U;
real<lower=0> sd_conti;
vector[n_ordi-1] a_ordi[K_ordi];
vector<lower=0>[K_ordi] b_ordi;
real theta[obs];
real mu_conti[obs];
real<lower=0, upper=1> psi[obs, K_ordi, n_ordi];
vector<lower=0, upper=1>[n_ordi] prob_y[obs, K_ordi];
// construct the latent variable theta
for (i in 1:obs)
theta[i] <- beta0[1] + beta0[2]*treat[i] + U[subject[i], 1] +
(beta1[1] + beta1[2]*treat[i] + U[subject[i], 2])*time[i];
// construct the means for the continuous variables
for (i in 1:obs)
mu_conti[i] <- a_conti + b_conti*theta[i];
// construct the probability vector for the remaining ordinal variables
a_ordi[1, 1] <- 0;
for (l in 2:(n_ordi-1)) a_ordi[1, l] <- a_ordi[1, l-1] + delta[1, l-1] ;
for (k in 2:K_ordi) {
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a_ordi[k, 1] <- a_ordi_temp;
for (l in 2:(n_ordi-1)) a_ordi[k, l] <- a_ordi[k, l-1] + delta[k, l-1];
}
b_ordi[1] <- 1;
for (k in 2:K_ordi) b_ordi[k] <- b_ordi_temp;
for (i in 1:obs) {
for (k in 1:K_ordi) {
for (l in 1:(n_ordi-1)) {
psi[i, k, l] <- inv_logit(a_ordi[k, l] - b_ordi[k]*theta[i]);
}
psi[i, k, n_ordi] <- 1;
prob_y[i, k, 1] <- psi[i, k, 1];
for (l in 2:n_ordi) {prob_y[i, k, l] <- psi[i, k, l] - psi[i, k, l-1];}
}
}
sd_conti <- sqrt(var_conti);
sig1 <- sqrt(var1);
sig2 <- sqrt(var2);
// construct the variance-covariance matrix
Sigma_U[1,1] <- sig1*sig1;
Sigma_U[1,2] <- rho*sig1*sig2;
Sigma_U[2,1] <- Sigma_U[1,2];
Sigma_U[2,2] <- sig2*sig2;
}
model {
real h[N_train];
real S[N_train];
real LL[N_train];
Y_conti ~ normal(mu_conti, sd_conti);
for (i in 1:obs) {
for (k in 1:K_ordi) {
Y_ordi[i, k] ~ categorical(prob_y[i, k]);
}
}
// construct random effects
U ~ multi_normal(zero, Sigma_U);
// construct survival part
for (i in 1:N_train) {
h[i] <- exp(gamma*age_pts[i] + nu*(beta0[1] + beta0[2]*treat_pts[i] + U[i, 1] +
(beta1[1] + beta1[2]*treat_pts[i] + U[i, 2])*tee[i]))*h0;
S[i] <- exp(-h0*exp(gamma*age_pts[i]+nu*(beta0[1]+beta0[2]*treat_pts[i]+U[i, 1])) *
(exp(nu*(beta1[1]+beta1[2]*treat_pts[i]+U[i, 2])*tee[i])-1) / (nu*(beta1[1]+beta1[2]*treat_pts[i]+U[i, 2])));
LL[i] <- log(pow(h[i],event[i])*S[i]); // event=1 for event; 0 for censored
}
increment_log_prob(LL);
// construct the priors
beta0 ~ normal(0, 10);
beta1 ~ normal(0, 10);
var1 ~ inv_gamma(0.01, 0.01);
var2 ~ inv_gamma(0.01, 0.01);
rho ~ uniform(-1, 1);
var_conti ~ inv_gamma(0.01, 0.01);
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h0 ~ gamma(0.01, 0.01);
nu ~ normal(0, 10);
gamma ~ normal(0, 10);
for (i in 1:(n_ordi-2)) delta[1, i] ~ normal(0, 10) T[0,] ;
for (k in 2:K_ordi) {
b_ordi_temp ~ uniform(0, 10);
a_ordi_temp ~ normal(0, 10);
for (i in 1:(n_ordi-2)) delta[k, i] ~ normal(0, 10) T[0,] ;
}
}
Full Conditionals
For illustration purpose, we assume that there are one continuous outcome (denoted by yi1(t)) and
two ordinal outcomes (denoted by yi2(t) and yi3(t), respectively), while model (3) is formulated as
θi(t) = X i(t)β +Zi(t)ui. Assuming non-informative prior distribution for the parameter vector Θ,
denoted by f(Θ), the joint likelihood is
L(Θ; ·) = p(y|u)p(u)f(Θ)
∝
I∏
i=1
{ Ji∏
j=1
p
[
Yi1(tij) = yi1(tij)
]
p
[
Yi2(tij) = yi2(tij)
]
p
[
Yi3(tij) = yi3(tij)
]}{
hi(ti)
δiSi(ti)
}
p(ui)
=
I∏
i=1
Ly1Ly2Ly3LS · p(ui),
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where
Ly1 =
Ji∏
j=1
1√
2piσ2ε
exp
{
−
[
yi1(tij)− a1 − b1θi(tij)
]2
2σ2ε
}
,
Lyk =
Ji∏
j=1
nk∏
l=1
p
[
Yik(tij) = l
]I[Yik(tij)=l]
=
Ji∏
j=1
nk∏
l=1
{
p
[
Yik(tij) ≤ l|θi(tij)
]
− p
[
Yik(tij) ≤ l − 1|θi(tij)
]}I[Yik(tij )=l]
=
Ji∏
j=1
[{
1− expit
[
ak(nk−1) − bkθi(tij)
]}I[Yik(tij )=nk]
·
nk−1∏
l=2
{
expit
[
akl − bkθi(tij)
]
− expit
[
ak(l−1) − bkθi(tij)
]}I[Yik(tij )=l]
·
{
expit
[
ak1 − bkθi(tij)
]}I[Yik(tij )=1]]
, k = 2, 3,
LS =
{
h0(ti) exp
[
W iγ + νθi(ti)
]}δi
exp
[
−
∫ ti
0
h0(s) exp
[
W iγ + νθi(s)
]
ds
]
,
p(ui) =
1
2pi
√
|Σ|
exp
[
−
1
2
u′iΣ
−1ui
]
,
expit(·) =
exp(·)
1 + exp(·)
.
The full conditionals of all parameters are
1. f(a1|others) ∝ N
(∑I
i=1
∑Ji
j=1
[
yi1(tij )−b1θi(tij )
]
NT
,
σ2ε
NT
)
;
2. f(b1|others) ∝ N
(∑I
i=1
∑Ji
j=1
[
yi1(tij)−a1
]
θi(tij )
∑I
i=1
∑Ji
j=1 θi(tij)
2
,
σ2ε
∑I
i=1
∑Ji
j=1 θi(tij)
2
)
;
3. f( 1
σ2ε
|others) ∝ Gamma
(
NT
2
+ 1,
∑I
i=1
∑Ji
j=1
[
yi1(tij)−a1−b1θi(tij)
]2
2
)
;
4. [a2, b2|others] ∝
∏I
i=1 Ly2 ;
5. [a3, b3|others] ∝
∏I
i=1 Ly3 ;
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6. [β|others] ∝
∏I
i=1 Ly1Ly2Ly3LS ;
7. [γ, ν|others] ∝
∏I
i=1 LS;
8. [ui|others] ∝
{∏Ji
j=1 p
[
Yi1(tij) = yi1(tij)
]
p
[
Yi2(tij) = yi2(tij)
]
p
[
Yi3(tij) = yi3(tij)
]}
LS · p(ui);
9. [Σ|others] ∝
∏I
i=1 p(ui),
where NT =
∑I
i=1 Ji.
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